Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study (Q34091370)

31 July 2017

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study (English)

1 reference

31 July 2017

0 references

2

A Mocroft

1 reference

31 July 2017

E Martinez

1

1 reference

31 July 2017

M A García-Viejo

3

1 reference

31 July 2017

J B Pérez-Cuevas

4

1 reference

31 July 2017

J L Blanco

5

1 reference

31 July 2017

J Mallolas

6

1 reference

31 July 2017

L Bianchi

7

1 reference

31 July 2017

I Conget

8

1 reference

31 July 2017

J Blanch

9

1 reference

31 July 2017

A Phillips

10

1 reference

31 July 2017

J M Gatell

11

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

31 July 2017

1 reference

31 July 2017

357

1 reference

31 July 2017

592-598

1 reference

31 July 2017

9256

1 reference

Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Sonographic assessment of regional fat in HIV-1-infected people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Changes in use of antiretroviral therapy in regions of Europe over time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Total body potassium in aging humans: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Studies in the distribution of body fat: I. Effects of age, sex, and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Body fat distribution in healthy young and older men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Fat distribution and metabolic changes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

The effect of protease inhibitors on weight and body composition in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Effect of indinavir on HIV-related wasting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904056-3

7 January 2021

10.1016/S0140-6736(00)04056-3

Identifiers

DOI

1 reference

31 July 2017

1 reference